Denosumab is a long-term option for the management of parathyroid carcinoma-related refractory hypercalcemia
QJM
.
2017 Jan;110(1):53-54.
doi: 10.1093/qjmed/hcw206.
Epub 2016 Dec 22.
Authors
A Fountas
1
,
S Tigas
2
,
A Tsatsoulis
2
Affiliations
1
From the Department of Endocrinology, University Hospital of Ioannina, Ioannina, Greece thanasisfountas@gmail.com.
2
From the Department of Endocrinology, University Hospital of Ioannina, Ioannina, Greece.
PMID:
28011856
DOI:
10.1093/qjmed/hcw206
No abstract available
Publication types
Letter
Comment
MeSH terms
Antibodies, Monoclonal, Humanized
Denosumab
Humans
Hypercalcemia*
Paraneoplastic Syndromes
Parathyroid Hormone
Parathyroid Neoplasms*
Substances
Antibodies, Monoclonal, Humanized
Parathyroid Hormone
Denosumab